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(SERT), blocking the reabsorption of serotonin by the presynaptic neuron and increasing serotonin levels
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of maternal SSRI exposure and the risk for altered neurodevelopment and associated behaviours in
offspring. While the current body of evidence suggests that maternal SSRI treatment may cause
perturbations to the neurobiology, behaviour and ultimately risk for neurodevelopmental disorders in
exposed offspring, conflicting findings do exist and the evidence is not conclusive. However, given the
increasing incidence of depression and number of women prescribed ADDs during pregnancy, further
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Abstract
Approximately 10% of pregnant women are prescribed antidepressant drugs (ADDs), with
selective serotonin reuptake inhibitors (SSRIs) the most widely prescribed. SSRIs bind to the
serotonin transporter (SERT), blocking the reabsorption of serotonin by the presynaptic
neuron and increasing serotonin levels in the synaptic cleft. The serotonergic system
regulates a range of brain development processes including neuronal proliferation,
migration, differentiation and synaptogenesis. Given the presence of SERT in early brain
development, coupled with the ability of SSRIs to cross the placenta and also enter breast
milk, concerns have been raised regarding the effects of SSRI exposure on the developing
foetus and newborns. In this review, we evaluate preclinical and clinical studies that have
examined the effects of maternal SSRI exposure and the risk for altered neurodevelopment
and associated behaviours in offspring. While the current body of evidence suggests that
maternal SSRI treatment may cause perturbations to the neurobiology, behaviour and
ultimately risk for neurodevelopmental disorders in exposed offspring, conflicting findings
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do exist and the evidence is not conclusive. However given the increasing incidence of
depression and number of women prescribed ADDs during pregnancy, further investigation
into this area is warranted.
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1.1 Introduction. Antidepressant drugs (ADDs) are currently one of the most widely
prescribed drug classes worldwide, administered to over 10% of the population for the
treatment of clinical depression and anxiety-related disorders (Moore et al., 2009; Olfson
and Marcus, 2009). Similarly, 8-10% of pregnant women are prescribed ADDs for the
treatment of depression (Cooper et al., 2007; Huybrechts et al., 2013). With the overall
incidence of depression significantly rising over the last several decades, this value may
continue to increase (Huybrechts et al., 2013; Kessler, 2003). While various classes of ADDs
exist, selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed to
pregnant women (in ~80% of cases) (Huybrechts et al., 2013; Mitchell et al., 2011) and have
been considered moderately safe for antenatal use (Oberlander et al., 2009). However,
recent analyses indicate that maternal use of SSRIs, particularly paroxetine, is associated
with greater risk of structural neuroteratogenic effects (Reefhuis et al., 2015). SSRIs, such as
fluoxetine, sertraline, and citalopram (the most commonly prescribed SSRIs during
pregnancy (Patil et al., 2011) bind to the serotonin transporter (SERT), blocking the
reabsorption of serotonin by the presynaptic neuron and increasing serotonin levels in the
synaptic cleft (Hiemke and Härtter, 2000) (Figure 1). While SSRIs cause acute elevations in
serotonin concentrations, the antidepressant properties of SSRIs are largely thought to be
elicited by downstream mechanisms, such as increases in brain derived neurotrophic factor
(BDNF) and subsequent neurogenesis in the prefrontal cortex (PFC) and hippocampus
(Martinowich and Lu, 2007). The serotonergic system and other downstream effectors, such
as BDNF, are also critical for normal neurodevelopment. This raises concerns about
exposure of the developing foetus and newborns to SSRIs as it has been shown that SSRIs
administered during pregnancy cross the placenta (Heikkinen et al., 2002) and are excreted
in breast milk (Hendrick et al., 2001; Kim et al., 2006). This concern is accentuated by studies
demonstrating associations between abnormal neurodevelopment of the serotonergic
system and several psychiatric and behavioural disorders, such as Autism Spectrum Disorder
(ASD) (Hranilovic et al., 2007; Mulder et al., 2004; Schain and Freedman, 1961), AttentionDeficit Hyperactivity Disorder (ADHD) (Banerjee et al., 2006; Oades et al., 2002; Retz et al.,
2008), anxiety and depression (Caspi et al., 2003; Olivier et al., 2011) and schizophrenia
(Bleich et al., 1988; Ikeda et al., 2005).
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1.2 Development of the Serotonergic System
The serotonergic system plays an important role in early brain development and is critical to
a range of processes, including neuronal proliferation, migration, differentiation and
synaptogenesis (Vitalis and Parnavelas, 2003; Whitaker-Azmitia, 2001). Serotonergic
neurons and receptors appear in the human brain by gestational week 5 (Figure 2); it is one
of the earliest monoaminergic systems generated during development (Gaspar et al., 2003;
Lambe et al., 2011; Sundström et al., 1993; Whitaker-Azmitia, 2001). By gestational week
15, serotonin cell bodies are in their typical organisation in the raphe nuclei, comprised of
nine distinct cell groups spanning from the medulla oblongata through to the midbrain. The
caudal division of cell bodies (B1-B5) project serotonergic fibres to the spinal cord, whilst
the rostral division (B6-B9) provides the major ascending serotonergic fibres to areas
throughout the forebrain, including the cerebral cortex, hippocampus and basal ganglia, and
account for 85% of all serotonergic neurons (Glover and Clinton, 2016; Hornung, 2003; Törk,
1990) (Sodhi and Sanders-Bush, 2004). Serotonin signals through 7 receptor families, 5-HT17,

most of which are G-protein coupled, except the ionotropic 5HT3 receptor subtype (Figure

1). The action of serotonin in the synaptic cleft is terminated by its reuptake by presynaptic
SERT and subsequent metabolism by monoamine oxidase A (MAO-A) to 5hydroxyindoleacetic acid (5-HIAA).
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Figure 1. Selective serotonin reuptake inhibitors (SSRIs) block the serotonergic transporter
(SERT), which inhibits the reuptake of serotonin, raising synaptic serotonin concentrations
that causes prolonged and exaggerated serotonin receptor activation. Serotonin exerts its
effects via a myriad of g-protein coupled receptors (5HTR1-2, 4-7) and ionotropic receptor
(5HTR3) subclasses. (a) Serotonin-containing vesicles fuse with the pre-synaptic membrane;
(b) spilling their contents into the synaptic cleft. (c) SERT removes serotonin from the
synaptic cleft, modulating the action of serotonin on its receptors. (d) SSRIs bind to SERT and
inhibit removal of serotonin from the cleft. (e) Activation of presynaptic and (f) (g)
postsynaptic serotonin receptors exerts varying inhibitory and excitatory effects depending
on the subclass and location, and regulates synaptic transmission and associated signaling
cascades.

In the human brain, SERT expression begins in parallel with the emergence of serotonergic
neurons; SERT positive fibres originating from the raphe nucleus reach the telencephalon at
gestational week 8, the subplate at gestational week 10 and the cortical plate at gestational
week 13 (Verney et al., 2002). A similar neurodevelopmental pattern has been
demonstrated in rodents (Figure 2); SERT expression arises in the serotonergic neurons of
the raphe nuclei at mid-gestation (embryonic day 13) (Hansson et al., 1998; Rubenstein,
1998) and serotonin fibers project into the telencephalon by embryonic day 17, passing
through the septal areas and spreading throughout the cerebral cortex (Sodhi and SandersBush, 2004).
5

Figure 2. Schematic of SERT expression in rodents and humans from early gestation to
adulthood. (a) In rodents, SERT expression follows a similar neurodevelopmental pattern as
humans, beginning in the raphe neurons at Embryonic Day (ED) 13 then extending to nonserotonergic neurons at ED17; SERT expression on non-serotonergic neurons ceases in the
rat brain by postnatal day (PN)12. (b) In humans, SERT expression arises in raphe neurons
corresponding with the development of the serotonergic system at gestational week (GW) 5,
and remains through to adulthood. At ~GW12, SERT expression arises in non-serotonergic
thalamocortical neurons. Whether transient SERT expression occurs in other nonserotonergic neurons in humans, similar to the rodent brain, remains to be determined.
Figure adapted from Homberg et al., (2009).

While SERT is largely expressed on serotonergic neurons throughout neurodevelopment and
maturity, it is also transiently expressed on non-serotonergic neurons. In the rodent brain,
SERT expression has been shown to appear on non-serotonergic neurons, including
glutamatergic neurons of thalamocortical pathways, pyramidal neurons in the prefrontal
cortex and hippocampus (Chen et al., 2016, 2015), and also projection neurons of the
somatosensory and corticolimbic systems, from approximately embryonic day 17 (Homberg
et al., 2010; Narboux-Nême et al., 2008). Developmental SERT expression on non6

serotonergic neurons in the rodent brain ceases in the first two weeks of postnatal life
(equivalent to birth in humans (Semple et al., 2013), and is localised to serotonergic neurons
in the mature brain (Narboux-Nême et al., 2008). Likewise in the human brain, an
anatomically distinct set of non-serotonergic thalamocortical axons (i.e. internal capsule and
corona radiata) have been observed to transiently express SERT between gestational weeks
12 and 14 (Verney et al., 2002). Whether this transient expression of SERT on nonserotonergic corticolimbic and somatosensory neurons also occurs in the human brain has
not yet been determined.
The presence of SERT on non-serotonergic neurons and their ability to transiently capture
serotonin during this early time period alludes to the possible involvement of serotonin in
key neurodevelopmental processes of non-serotonergic systems. Studies have shown that
serotonin plays a key role in the development of the neocortex by modulating the migration
of cortical neurons (Riccio et al., 2011), and the formation of dendritic spines and branches,
as well as dendritic length, in the hippocampus and cerebral cortex (Sodhi and SandersBush,

2004;

Vitalis and

Parnavelas,

2003).

During telencephalic

development,

monoaminergic afferents and SERT-expressing thalamocortical axons are in close proximity
along the internal capsule. These SERT-expressing thalamocortical axons have been shown
to take up serotonin, and have been implicated in the migration and proliferation of
developing glutamatergicneurons, potentially through subsequent serotonin release (Edgar
and Price, 2001; Vitalis and Parnavelas, 2003; Whitworth et al., 2002). In addition, serotonin
has been shown to modulate the response of developing thalamocortical axons to
guidancecues, such as Netrin-1, via the serotonin receptor (5HTR1B/1D) (Bonnin et al., 2007).
The serotonin 5HT1A receptor is highly expressed in the telencephalic proliferative zone in
early development, where it modulates cell division and proliferation (Hillion et al., 1994;
Lidow and Rakic, 1995; Varrault et al., 1992; Vitalis and Parnavelas, 2003). Recently, studies
have shown that serotonin influences the speed and trajectory of migrating GABAergic
cortical interneurons via activation of 5HT3A receptors (Murthy et al., 2014), and also
encourages the differentiation of early progenitor cells into glutamatergic neurons in the
developing cerebral cortex (Lavdas et al., 1997). Taken together, these findings clearly
implicate the serotonergic system as a key regulator of neurodevelopment, of which
potential alterations caused by SSRI-exposure are summarized in Figure 3.
7

Considering the critical role of the serotonergic system in neurodevelopment, it is feasible
that manipulation of the serotonergic system during early development has the potential to
cause broader disruptions in brain structure and circuitry and lead to associated
disturbances in brain function and behaviour. Indeed, increased levels of serotonin during
early development, modelled utilising SERT-knockout mice, was found to cause abnormal
development of thalamocortical axons and underdevelopment of the somatosensory
cortical barrels (Gaspar et al., 2003; Persico et al., 2001), as well as increases in anxiety- and
depressive-like behaviours (Ansorge et al., 2004). Behavioural and biological alterations in
other serotonergic system knockout models have also been reported with mutants showing
increased (5HT1A receptor knockout) and decreased (5HT2C and 5A receptor knockout) anxiety
levels, reductions in GABAA receptor binding and hippocampal neurogenesis (5HT1A receptor
knockout), as well as increased aggression in MAO-A (the enzyme responsible for 5HT
degradation) knockout mice (for review see Gaspar et al., 2003). Therefore, altering the
normal function of the serotonergic system can have broad implications on behavioural and
biological phenotypes.

2.1 The behavioural and biological effects of maternal SSRI treatment on exposed
offspring: Evidence from human studies
Taking into account the significant neurodevelopmental role that the serotonergic system
plays and the widespread expression of SERT during gestation, manipulation to the
serotonergic system could have major implications for human neurodevelopment and
associated disorders. SSRIs administered during pregnancy are transferred across the
placenta, resulting in prenatal SSRI exposure to the foetus; however, the extent and
consequences of this exposure on the developing brain are unclear (Hendrick et al., 2001;
Kim et al., 2006). Studies examining SSRI concentrations in foetal cord blood from treated
mothers have reported concentrations of at least 50% compared to maternal levels (for
review see Ewing et al., 2015). Additionally, two enzymes responsible for the metabolism of
SSRIs in humans, cytochrome P450 2C and 2D6 (CYP2C and CYP2D6), are low or
8

undetectable in the foetal liver but increase progressively during early life (Hines and
McCarver, 2002; Sadler et al., 2016). Therefore, the foetus and neonate may be particularly
sensitive to maternal SSRI exposure due to an inability to eliminate drugs through
metabolism by the liver (Hiemke and Härtter, 2000; Kim et al., 2006).
Several studies observing birth outcomes of infants exposed to SSRIs in-utero (as early as
the 1st trimester and throughout pregnancy) have identified an increased risk for preterm
delivery (Davis et al., 2007; Huang et al., 2014; Maschi et al., 2008; Reis and Källén, 2010),
low Apgar scores (Casper et al., 2011, 2003; Jensen et al., 2013; Källén, 2004), increased risk
for low birth weight (Huang et al., 2014; Oberlander et al., 2006; Reis and Källén, 2010),
frequent intensive care unit admissions (Casper et al., 2011; Galbally et al., 2009), neonatal
abstinence syndrome (i.e. effects of withdrawal caused by the cessation of SSRI exposure)
(Levinson-Castiel et al., 2006; Nordeng et al., 2001) and risk for cardiac defects (Källén and
Otterblad Olausson, 2007; Kornum et al., 2010; Pedersen et al., 2009). Whilst other studies
report no significant association between prenatal SSRI exposure and cardiovascular
anomalies (Davis et al., 2007) and pre-term birth (Hendrick et al., 2003), a recent study by
Reefhuis et al., (2015), suggested that the potential teratogenicity of SSRIs was drugspecific. Using a Bayesian analysis approach, combining results from independent published
studies together with data from a multicentre population-based case-control study of birth
defects, the authors concluded that only fluoxetine and paroxetine were associated with
increased risk of cardiac defects, while paroxetine alone was associated with an increased
risk for anencephaly and atrial septal defects (Reefhuis et al., 2015).
While traditional assessments of drug safety during pregnancy have focused on structural or
teratogenic defects to exposed offspring, more recent research has focused on the possible
long-term

effects

on

brain

function,

behaviour

and

the

development

of

neurodevelopmental disorders. Several studies have examined the effects of maternal
antidepressant drug treatment on offspring behaviour and risk of neurodevelopmental and
psychiatric disorders, with a primary focus on ADHD and ASD (Table 1). These studies exhibit
an apparent division into longitudinal studies that track the development of offspring from
antidepressant-treated mothers and studies that track the familial history of offspring with
ADHD and ASD. While the results of these studies are varied, there is evidence to suggest a
possible association between maternal antidepressant drug use and ASD and/or ADHD and
9

their associated behaviours in exposed offspring. Four out of eight retrospective studies
reported significant increases in the risk of ASD following prenatal exposure to
antidepressant (primarily SSRI) treatment (Boukhris et al., 2016; Croen et al., 2011; Gidaya
et al., 2014; Harrington et al., 2014). Of these studies, two found that maternal SSRI
treatment was associated with a 2- fold increased risk in the development of ASD in
offspring, with a three-fold increase in risk observed when exposure occurred in the first
trimester (Croen et al., 2011; Harrington et al., 2014). Moreover, Croen et al., (2011) found
no increase in the risk of ASD in offspring of mothers with a history of depression or any
other health disorder in absence of prenatal SSRI treatment, suggesting that SSRI exposure
plays an influential role (Croen et al., 2011). Conversely, another study reported that
maternal history of depression was associated with a greater risk for ASD in offspring, with
an even greater risk observed when combined with maternal SSRI treatment (Rai et al.,
2013). While these studies are somewhat conflicting, SSRI treatment could be an indicator
of maternal depressive symptom severity that could also contribute to the greater risk of
ASD reported in these studies. Interestingly, one study reported that SSRI exposure prior to,
but not during pregnancy, increased the risk for ASD in offspring (Clements et al., 2015),
further suggesting that the observed risk for ASD as the result of prenatal SSRI exposure is
possibly confounded by severity of maternal mental illness. Unfortunately, the measure in
severity of maternal mental illness in these studies was based on measures such as
frequency of past hospital admissions, which may be insufficient to truly capture symptom
severity differences between participants. Nonetheless, Croen et al (2011) did report an
increase in risk of ASD in offspring exposed to SSRIs in pregnancy, despite taking into
consideration maternal mental health symptom severity and history (Croen et al., 2011)
suggesting that symptom severity and history alone may not influence the risks.
Of the retrospective studies that investigated cases of ADHD, two reported a significantly
increased risk associated with SSRI exposure and this behavioural disorder (Clements et al.,
2015; Figueroa, 2010). One study reported that SSRI treatment during, but not prior to
pregnancy was associated with an increased risk for ADHD in offspring (Clements et al.,
2015), suggesting that exposure plays an influential role. In comparison to these findings,
another study reported an increased risk of ADHD in children of women exposed to SSRIs
postnatally only, proposing greater emphasis on the influence that maternal mood disorders
10

play during pregnancy; however, the influence of SSRI-exposure through breast milk on
offspring cannot be ruled out (Figueroa, 2010). Differences in sample sizes, ages and
methodology may have contributed to the conflicting findings. For example Clements et al.,
(2015) recruited data from cases of ADHD (n= 2,243) in offspring aged 2-19 years, then
identified those exposed to maternal SSRIs (n= 62), whilst Figueroa et al., (2010) recruited
data from pregnancies with SSRI exposure (n= 916) and aligned with cases of ADHD (n= 23)
in offspring aged 0-5 years.
Collectively, with the exception of Malm et al., (2016), who reported an increased risk for
depression in adolescent offspring exposed prenatally to SSRIs, the retrospective studies
largely neglect the assessment of symptoms specific to anxiety and depressive disorders or
later adolescent ages, and focus instead on ASD, ADHD and the juvenile ages, making it
difficult to posit the potential longer term effects of maternal SSRI exposure. In addition,
though the majority of the retrospective studies indicate that maternal SSRI exposure may
increase the risk for developmental disorders in offspring, it is obvious that the exposure
period that confers the greatest risk is much deliberated.
While retrospective studies provide the opportunity for large sample sizes and relative ease
in data collection, they are limited by their inability to confirm SSRI use/compliance or
symptom severity of maternal mood disorders during pregnancies. In comparison, despite
lower samples sizes, longitudinal studies have the added benefit of examining more specific
subject behaviours and measures of neurodevelopment and associated disorders. Of the ten
published longitudinal studies, five reported no significant effects of SSRI exposure on
behavioural parameters, as measured using the Bayley Scales of Infant and Toddler
Development Instrument (BSID) administered by trained clinicians (Austin et al., 2013;
Casper et al., 2003; Galbally et al., 2011) and the Child Behaviour Checklist (CBCL), a
subjective, observational questionnaire completed by subject parents or caregivers (Misri et
al., 2006; Nulman et al., 2012). The BSID assesses motor, language and cognitive
development of infants and toddlers aged 0-3.5, whilst the CBCL aims to measure problem
behaviour in children characterized by internalizing, such as withdrawal and anxiety, and/or
externalising, such as delinquent or aggressive behaviours (Nøvik, 1999). These studies
include small sample sizes (n=13-35) that may have limited statistical power to detect any
associations. Conversely, five studies with larger sample sizes (n=28-5,531) have reported
11

significant associations between maternal SSRI exposure and behavioural disturbances in
offspring, including autistic traits, anxiety and externalizing behaviours. These studies were
conducted in cohorts of slightly older children (up to 6 years of age) assessed using the CBCL
(Hanley et al., 2015; Hermansen et al., 2016; Marroun et al., 2014; Oberlander et al., 2010)
and BSID (Hanley et al., 2013). The question of whether the conflicting nature of these
findings is due to the different methodology employed, or other factors such as sample size
and age of subjects, needs further investigation. Furthermore, it must be acknowledged that
several longitudinal studies lack effective comparison groups that enable separation of the
effects of SSRI exposure from the effects of maternal depression (Austin et al., 2013;
Galbally et al., 2011; Hanley et al., 2013; Misri et al., 2006; Oberlander et al., 2010). In
addition, the longitudinal studies only examine the juvenile years and as such emotional
disturbances, such as depression and anxiety, that commonly emerge during adolescent
years, were not measured (Paus et al., 2008). Therefore, further studies examining later
time periods would help provide a complete spectrum of potential neurobehavioural
alterations associated with developmental SSRI exposure.

12

Table 1: Effects of maternal SSRI exposure on offspring neurodevelopmental disorders: evidence from human studies.
Study

Antidepressants

Participants (n) with or
without symptomology of
Major Depressive Disorder
(+/- MDD)

Age of
offspring
studied

Findings

n = 35 treated/exposed
+ MDD

17-24
months

Nil significant effects of in-utero SSRI exposure on
motor, language or cognitive development – assessed
using the Bayley Scales of Infant and Toddler
Development instrument (BSID-III).

6-40
months

Nil significant effects of in-utero SSRI exposure on
infant neurodevelopmental outcomes measuring motor,
language and cognitive development - assessed using
BSID-II.

4-5 years

Nil significant differences between groups in

Longitudinal Studies
Austin et al.,
(2013)

SSRIs
(Fluoxetine, Sertraline,
Citalopram, Escitalopram,
Paroxetine, Fluvoxamine)

n = 23 controls untreated
- MDD

SNRI
(venlafaxine)
TCA
(Dothiepin)
Casper et al.,
(2003)

SSRIs
(Fluoxetine, Sertraline,
Paroxetine, Fluvoxamine)

n = 31 treated/exposed
+ MDD
n = 13 controls untreated
+ MDD

Misri et al.,

SSRIs

n = 22 treated/exposed
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(2006)

(Fluoxetine, Sertraline,
Paroxetine)

+ MDD

internalizing behaviours, based on parental/teacher selfreport using the Child Behaviour Checklist (CBCL) (which
is designed to screen for psychological disorders and
associated behaviours, including anxiety, depression,
social interaction, aggressiveness, attention and
cognition)(Mazefsky et al., 2011)

n = 14 controls untreated
-MDD

Oberlander et
al., (2010)

SSRIs (fluoxetine, paroxetine,
sertraline, venlafaxine,
Citalopram)

n = 33 treated/exposed
+ MDD

3 years

Children exposed to SSRIs and maternal depressed
mood had significantly increased internalizing
behaviours reported using the CBCL.

19-35
months

Children exposed to SSRIs scored lower on motor
subscales, particularly fine motor and gross motor, using
the BSID-II. Nil significant effects on infant language and
cognitive development.

5-6 years

Children exposed to SSRIs had significantly increased
internalizing and externalizing behaviour measured by
the CBCL.

n = 42 controls untreated
- MDD

Galbally et
al., (2011)

SSRIs
(sertraline, venlafaxine,
citalopram)

n = 22 treated/exposed
+ MDD
n = 19 controls untreated
- MDD

Hermansen et SSRIs (Fluoxetine, Paroxetine,
al., (2016)
Sertraline, Escitalopram and
citalopram)
SNRI (Venlafaxine)
Mirtazapine

n = 28 treated/exposed
+ MDD
n = 42 controls untreated
+ MDD
n = 33 controls untreated
- MDD
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Hanley et al.,
(2015)

El Marroun et
al., (2014)

SSRIs
(Fluoxetine, Paroxetine,
Sertraline, Venlafaxine,
Citalopram)

n = 44 treated/exposed
+ MDD

SSRI
(paroxetine, fluoxetine,
sertraline, fluvoxamine and
citalopram)

n = 69 treated/exposed
+ MDD

3 – 6 years Children exposed had significantly increased anxiety
and internalizing behaviours at 3 and 6 years of age,
measured using the CBCL.

n = 66 controls untreated, of
which n = 10 +MDD
1.5-6
years

Prenatal SSRI exposed offspring showed higher risk for
autistic traits and development of pervasive
developmental problems compared to those exposed to
maternal depression only – measured by the CBCL and
the Social Responsiveness Scale, which focuses
specifically on dimensions that relate to that of autism
spectrum disorders, such as social cognition,
communication and autistic mannerism (Constantino et
al., 2003).

10 months

Children exposed to SSRIs scored significantly lower on
gross motor, social-emotional and adaptive behaviour
using the BSID-III, and after controlling for MDD.

3-6 years

IQs of children exposed to venlafaxine and SSRIs were
significantly lower compared to children of mothers
with untreated MDD and controls with no history of
MDD or ADD treatment.

n = 376 controls untreated
+ MDD
n = 5,531 controls untreated
- MDD

Hanley et al.,
(2013)

Nulman et al.,
(2012)

SSRIs
(paroxetine, fluoxetine,
sertraline, venlafaxine,
citalopram)

n = 31 treated/exposed
+ MDD

SSRIs
(sertraline, paroxetine,
citalopram, fluoxetine,

n = 62 treated/exposed (SSRI)
+ MDD

n = 52 controls untreated
- MDD

n = 62 treated/exposed (SNRI)
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fluvoxamine).
SNRIs
(venlafaxine)

+ MDD
Nil significant differences in cognitive or behavioural
abnormalities of exposed groups assessed using the
Child Behaviour Checklist.

n = 54 controls untreated
+ MDD
n = 62 controls untreated
- MDD

Retrospective Studies
Hviid et al.,
(2013)

SSRIs (fluoxetine, sertraline,
paroxetine, citalopram,
escitalopram, fluvoxamine)

n = 6,068 SSRI exposed of
which
n= 835 mothers + MDD
n= 52 offspring + ASD

0 – 10
years

SSRI use during pregnancy was not associated with an
altered risk of ASD.

5-9 years

Prenatal exposure to SSRIs was not associated with a
significantly altered risk for ASD in offspring.

n = 620,807 control of which
2647 mothers + MDD

Sorensen et
al., (2013)

SSRIs, SNRI, TCA

n = 8,833 ADD exposed, of
which
n= 1,756 mothers + MDD
n= 104 + ASD
Of those exposed to ADD;
n = 7,506 SSRI exposed
n = 673 SNRI exposed
n = 642 TCA exposed
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n = 646,782 controls, of which;
n= 4,324 mothers + MDD
n= 5,333 + ASD
Boukhris et
al., (2016)

SSRIs, SNRIs, TCA, Monoamine
Oxidase Inhibitors (MAOI)

n = 4724 ADD exposed, of
which;
n = 46 + ASD
n = 3290 mothers + MDD

0 – 11
years

SSRI use was associated with increased risk of ASD in
offspring, when exposed in the second and/or third
trimester only (HR 1.87), after accounting for
confounders.

4 – 12
years

In-utero SSRI exposure was not associated with
increased risk of ASD in offspring.

n = 140,732 controls, of which;
n = 1008 + ASD
n = 14,651 mothers + MDD
Brown et al.,
(2017)

SSRIs

n = 2837 pregnancies ADD
exposed, of which;
n = 1176 + Bipolar or MDD
n = 2364 other
depressive/anxiety disorder
n = 58 offspring +ASD
n = 33069 pregnancies without
ADD exposure, of which;
n = 3175 + Bipolar or MDD
n = 13589 other
depressive/anxiety disorder
n = 335 offspring +ASD
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Figueroa
(2010)

SSRIs, Bupropion, TCA

n = 1030 ADD exposed, of
which;
n = 28 +ADHD

0 – 5 years Significant increase in ADHD in offspring exposed to
SSRIs postnatally, and not before/during pregnancy (OR
2.04).
Significant increase in ADHD in offspring exposed to
Bupropion during pregnancy, and not before/after (OR
3.63).

n = 3532 children of mothers
+MDD, of which;
n = 88 +ADHD
n = 29, 329 children of mothers
–MDD, of which;
n = 239 +ADHD

Brandlistuen
et al., (2015)

SSRIs, TCA, Other

n = 141 ADD exposed, of which;
n = 90 +MDD

0-3 years

Significant increase in anxiety symptoms in offspring
exposed to ADDs (r=0.64, p<0.05 regression analysis)
after adjusting for MDD during pregnancy, MDD history,
smoking, alcohol and co-medication. Measured using the
CBCL.

2-19 years

ADD exposure during but not prior to pregnancy was
associated with ADHD (OR 1.69), after adjusting for
MDD

n = 20,039 not exposed, of
which;
n = 3831 +MDD
Clements et
al., (2015)

Antidepressants (categorized by
their 5-HT transporter affinity –

n = 1,377 ASD, of which
n= 128 ASD subjects had a
mother with history of + MDD

High: fluoxetine, paroxetine,
duloxetine, sertraline,
escitalopram.

n= 4,022 controls, of which
n= 225 subjects had mother +
MDD

Moderate: citalopram,
fluvoxamine, venlafaxine.

n = 2,243 ADHD, of which
n= 184 subjects had mother +
MDD

ADD use prior to pregnancy but not during was
associated with ASD (OR 1.91), after adjusting for MDD
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Low: nefazodone, bupropion,
mirtazapine).

Croen et al.,
(2011)

SSRI, TCA and DAA (dual action
ADD)

n = 5,631 controls, of which
n= 214 subjects had mother +
MDD
n = 298 ASD, of which 10
mothers + MDD

12 to 16
years

n = 1,507 controls, of which 44
mothers + MDD

Two-Fold increased risk of ASD associated with SSRI
exposure during the year prior to delivery (OR 2.2)
(including before and during pregnancy), with the
strongest effect associated with treatment in first
trimester (OR 3.8).
No increase in risk of ASD in children of mothers with a
history of mental health treatment and no SSRI use.

Gidaya et al.,
(2014)

SSRIs (fluoxetine, citalopram,
paroxetine, sertraline,
fluvoxamine, escitalopram).

n = 5,215 ASD, of which;
n = 76 SSRI exposed
n= 55 mothers + MDD

8-17 years

In utero exposure to SSRIs increased risk for ASD (OR
1.8), after adjusting for maternal depression and any
SSRI indication.

2 to 5
years

SSRI use associated with greater risk of ASD (OR 2.91),
with strongest association occurring with first-trimester
exposure (OR 3.22) and developmental delay in boys (OR
3.39) (authors report invalid sample size for girls)

n = 52,150 controls
Of which;
n = 365 SSRI exposed
n = 347 mothers + MDD

Harrington et
al., (2014)

SSRIs (fluoxetine, sertraline,
paroxetine, citalopram,
escitalopram)

n = 492 ASD, of which 122
mothers + MDD
n = 154 developmental delay,
of which 40 mothers + MDD
n = 320 controls, of which 67
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mothers + MDD

Malm et al.,
(2016)

SSRIs (fluoxetine, sertraline,
paroxetine, citalopram,
escitalopram, fluvoxamine)

n = 15,729 SSRI exposed, of
which;
n = 60 + ASD
n = 160 + ADHD
n = 60 + Depression
n = 65 + Anxiety

0 – 14
years

SSRI exposure was associated with increased rates of
depression in early adolescence (HR 1.78) but not with
ASD or ADHD.

0-17 years

Maternal history of depression was associated with a
higher risk of ASD in offspring (OR 1.49). Of the
subsample with available data on ADD exposure, this
association was limited to women reporting ADD use
during pregnancy.

n = 9,651 maternal psychiatric
disorder, no SSRI, of which;
n = 79 + ASD
n = 137 + ADHD
n = 30 + Depression
n = 39 + Anxiety
n = 31,394 controls, nil SSRI
exposure, nil maternal
psychiatric disorders, of which;
n = 100 + ASD
n = 124 + ADHD
n = 30 + Depression
n = 62 + Anxiety
Rai et al.,
(2013)

SSRI, TCA

n = 4,429 ASD, of which 44
mothers + MDD
n = 43,277 control, of which
272 mothers + MDD
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Abbreviations: ADD = Antidepressant Drug; ADHD = Attention Deficit Hyperactivity Disorder; ASD = Autism Spectrum Disorders; BSID = Bayley Scales of
Infant and Toddler Development instrument; HR = Hazards Ratio; MDD = Major Depressive Disorder; OR = Odds Ratio; SNRI = Serotonin and Norepinephrine
Reuptake Inhibitors; SSRI = Selective Serotonin Reuptake Inhibitors; TCA = Tricyclic Antidepressants.
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While there has been minimal investigation of the neuro-biological consequences of foetal
SSRI exposure, the limited studies that have been conducted (Bellissima et al., 2015;
Davidson et al., 2009; Laine et al., 2003; Oberlander et al., 2008; Pawluski et al., 2012, 2009)
have focused primarily on aspects of the hypothalamic-pituitary-adrenal (HPA) axis and
neurotransmitter metabolites in cord blood samples, with an absence of studies focusing on
longer term changes. One study reported significantly decreased serotonin and its main
metabolite, 5HIAA, by as much as 67% in the cord blood of SSRI exposed infants compared
to controls (Laine et al., 2003), providing evidence that SSRIs may not necessarily increase
foetal brain serotonin as it does in the adult brain. However, given that sources of foetal
serotonin are dynamic and switch progressively during development from exogenous
(placental) to endogenous (foetal raphe neurons) sources (Bonnin et al., 2011); caution
needs to be taken when interpreting levels of serotonin in cord blood. Furthermore, another
study reported a reduction in the dopamine metabolite, homovanillic acid (HVA), and a
borderline reduction in cord blood noradrenaline (Laine et al., 2003), suggesting that SSRI
exposure can influence neurotransmission systems beyond serotonin. The serotonergic
system is a key regulator of the HPA axis and corticotropin releasing hormone (CRH) release
is mediated by serotonergic transmission (Heisler et al., 2007b, 2007a). Accordingly, SSRI
exposed infants have exhibited significantly decreased levels of cortisol in cord blood
(Davidson et al., 2009) and in salivary samples at three months of age (Oberlander et al.,
2008).
Recent studies have investigated other potential markers of neurobiological alterations
caused by maternal SSRI exposure in human samples (Table 2). S100 calcium-binding protein
β (S100β) is an astroglial-derived neurotrophic factor used as a marker of CNS cellular
damage when detected at elevated biological concentrations (Kleindienst et al., 2007). One
study reported significantly increased S100β levels in maternal blood, amniotic fluid, cord
blood and neonatal peripheral blood throughout pregnancy, at birth and 24hours postnatal
following maternal treatment with the SSRI paroxetine compared to untreated controls
(Bellissima et al., 2015). In addition, infants showing major neurological symptoms (i.e.
hypotonia and seizures) at postnatal day 7 exhibited the highest blood S100β levels
(Bellissima et al., 2015). Separating these findings in SSRI-treated mothers from the effects
of innate maternal depression are difficult given that no control group for maternal
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depression was used (Bellissima et al., 2015), particularly when other studies suggest that
untreated depressed subjects display higher levels of S100β (Arolt et al., 2003; Grabe et al.,
2001). On the other hand, another study reported decreased S100β levels in cord blood
following SSRI exposure, even after controlling for maternal mood disorder, but reported
significantly higher maternal S100β levels in SSRI treated subjects compared with nontreated (Pawluski et al., 2009). The conflicting findings regarding neonatal S100β levels
between these two studies may be attributed to the specific SSRIs tested with Pawluski et
al., (2009) collectively examining a range of SSRIs, whereas Bellissima et al., (2015) included
data from those mothers treated with paroxetine only.
Finally, although levels of biological markers taken from blood provide some insight into the
potential peripheral neurochemical perturbations occurring as the result of SSRI exposure,
there is no guarantee that these peripheral measures accurately reflect changes in the
brain. Further studies investigating the long-term effects of SSRI exposure on central
neurotransmitter systems and their metabolites are required to elucidate the potential for
these drugs to manipulate the developing brain. This last point is compounded given the
purported role of the serotonergic system in the development of other systems, including
glutamate and GABA (refer to section 1.2) and its relationship with neurotrophic markers
such as BDNF, and their role in neurogenesis.
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Table 2: Effects of maternal antidepressant administration on biological measures in offspring: Evidence from human studies
Study

Antidepressants

Participants (n)

Measurements Taken

Main Findings

Bellissima et al.
(2015)

SSRI
(Paroxetine n = 75)

n = 75 SSRI exposed + MDD or
other mood disorders

S100β protein
concentrations assessed
in maternal blood,
amniotic fluid, cord blood
and neonatal peripheral
blood.

• Significant increase in S100β levels in
maternal blood, amniotic fluid, and arterial and
venous cord blood at all time points.

n = 231 controls untreated
- MDD or other mood disorders

Samples taken at:
-16-20, 27-30 and 35-40
weeks pregnancy
(maternal blood).

Davidson et al.
(2009)

SSRIs
(paroxetine n = 8,
fluoxetine n = 7,
citalopram n = 6)

n = 21 exposed (details of
maternal mood disorders
unknown)
n = 20 control untreated
- MDD or other mood disorders

- Birth (amniotic fluid)
- 24 hours postnatal
(arterial and venous cord
blood).
Birth (cord blood)
- cortisol
- Thyroid Stimulating
Hormone (TSH)
- Insulin-like growth factor
(IGF-1)
- Dehydroepiandrosterone
(DHEA)
Placenta

% Difference in median S100β levels
16-20 weeks (+233%)
27-30 weeks (+220%)
35-40 weeks (+157%)
Birth (+1425%)
24 hours (+829%)

• Significant decrease (-31%) in cord blood
cortisol levels in the SSRI exposed group.
• Significant increase (+31%) in cord blood TSH
levels in SSRI exposed group.
• Significantly lower (-70%) IGF-I level in infants
exposed to citalopram only.
• Significantly elevated (+100%) level of
placental (IGF-1R) in SSRI exposed group.
• Nil significant difference in DHEA and 5HIAA
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- IGF-1 receptor (IGF-1R)
Urine (newborn)
- 5-HIAA

Laine et al.
(2003)

SSRIs
(n=20 Fluoxetine;
n=20 Citalopram)

n = 20 SSRI exposed (n=10 +
MDD; n=10 + panic disorder)

Birth (cord blood)
- 5-HT
- 5-HIAA
- Homovanillic Acid (HVA)
(dopamine metabolite)
- Noradrenaline
- Prolactin

• Significantly decreased cord 5-HT (-67%), 5HIAA (-18%) and HVA (-23%), serum prolactin
(-29%) in the SSRI exposed infants compared
to control.
• Borderline significant decrease (-46%; p=0.05)
cord Noradrenaline in SSRI exposed.

• No significant differences in saliva cortisol
levels between infants during the time points
associated with the information processing task.

n = 45 control untreated
- MDD or other mood disorders

Cortisol collected at 3
months’ age (saliva) at
three daily time points,
before, during, and after
an information processing
task.

n = 36 exposed + MDD or other
mood disorders

An additional measure of
cortisol was taken the
next day in the
afternoon/evening.
Birth (cord blood)
- S100β pg/ml

n = 20 control untreated
- MDD or other mood disorders

Oberlander et
al. (2008)

Pawluski et al.
(2009)

SSRIs

SSRIs
paroxetine n =14,
fluoxetine n = 6,
sertraline n = 6,
citalopram n = 4

n = 31 SSRI exposed (maternal
mood disorder history not
stated)

• Evening cortisol was significantly lower (-65%)
in SSRI exposed infants compared to control.

• Prenatal SSRI exposure significantly lowered (16%) neonatal serum S100β levels compared to
controls.

n = 17 controls untreated
- MDD or other mood disorders
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Pawluski et al.,
(2012)

SSRIs

36 Weeks (n)
n = 47 control untreated - MDD
or other mood disorders
n = 29 exposed + MDD or other
mood disorders
Neonate (n)
n = 40 control untreated - MDD
or other mood disorders

Serum at 36 weeks and
neonates (cord blood)
- Cortisol-binding globulin
(CBG)
- Cortisol

• Significant increases in serum CBG (+33%) of
neonates exposed to SSRIs after vaginal
delivery.
• No significant differences in levels of other
measured parameters.

Saliva (infants 3month
old)
- cortisol

n = 25 exposed + MDD or other
mood disorders
Abbreviations: SSRIs = selective serotonin reuptake inhibitors, IGF-I = insulin-like growth factor, IGF-IR = insulin-like growth factor receptor, TSH = thyroid
stimulating hormone, 5-HT = 5-hydroxytryptamine, 5-HIAA = 5-hydroxyindoleacetic acid, HVA = homovanillic acid, DHPG = dihydroxyphenylglycine, S100β =
S100 calcium-binding protein B.
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2.2 Considerations for Human Studies
Human studies are invaluable to clarify the risks associated with maternal SSRI exposure; yet
they are confounded by the underlying maternal psychopathology and maternal stress or
adversities. Furthermore, human studies often omit or report difficulties measuring the
severity of maternal mood disorders, which may be phenotypically masked due to SSRI
treatment, and could represent a considerable influence over the observed effects of SSRI
exposure on offspring. As iterated by Petersen et al., (2014), SSRI use may be a marker of
severity of underlying mental illness and that may confound the interpretation of these
clinical findings. Therefore, careful consideration must be given to the interpretation of
clinical studies and their implications for the broader population, especially when inherent
difficulties in separating the effects of maternal SSRI exposure from confounding factors,
such as maternal depression, are often overlooked.
Maternal mood disorders and adversity themselves are factors associated with a greater risk
for obstetric complications, impaired pre- and post-natal care and the development of
psychopathologies in children (Ashman et al., 2002; Davalos et al., 2012; Glover, 2014;
Hammen and Brennan, 2003; Nulman et al., 2002; O’Connor et al., 2002). Systematic
reviews have shown that untreated maternal depression is associated with increased
markers of infant morbidity, including preterm birth, low birth weight, childhood emotional
and behavioural problems and poor cognitive development (Davalos et al., 2012; Gentile,
2015; Steer et al., 1992). Studies have also noted neurobehavioural consequences of
untreated maternal depression or maternal adversity on children, with some showing an
increased risk for internalizing behaviours (Ashman et al., 2002), decreased cognitive and
language development (Nulman et al., 2002), developmental delay (Deave et al., 2008) and
an increased risk for depression, anxiety, ADHD and ASD symptomology (Glover, 2014;
Hammen and Brennan, 2003; O’Connor et al., 2003, 2002; Rice et al., 2010; Rodriguez and
Bohlin, 2005; Ronald et al., 2011; Van den Bergh and Marcoen, 2004). Untreated maternal
depression can also have indirect effects on the offspring through means of unhealthy
maternal behaviours, for example studies have found a significant association with pregnant
women suffering from depression and cigarette, alcohol and cocaine use in some people
(Zuckerman et al., 1989); all well-known to detrimentally affect pregnancy outcomes
(Cnattingius, 2004; Eyler et al., 1998; Ornoy and Ergaz, 2010). Finally, prenatal depression
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remains one of the strongest risk factors for postnatal depression (Robertson et al., 2004); a
disorder linked to developmental problems and increased risk of depression in children
(Murray et al., 2011; Talge et al., 2007). Severe untreated depression, can also result in
suicide, which is a major cause of maternal death (Oates, 2003). Therefore, SSRIs continue
to be critically important to the health and well-being of mothers with depression and
accordingly, current clinical guidelines from the American Psychiatric Association advise
against the discontinuation of SSRI use in pregnancy (though switching from paroxetine may
be advised in some instances), particularly if the chance of psychopathological relapse is
high (Yonkers et al., 2009). Despite reports of increased risk associated with third trimester
SSRI exposure and teratogenic effects or neonatal abstinence syndrome, tapering of SSRI
dosage has also been recommended over discontinuation (Yonkers et al., 2009). Finally,
although some clinical studies report ~2-3x fold increases in risks for neurodevelopmental
disorders in offspring exposed to SSRIs (Boukhris et al., 2016; Clements et al., 2015; Croen et
al., 2011; Gidaya et al., 2014; Harrington et al., 2014), the fact remains that the overall
incidence/prevalence of these disorders in the population is relatively low (incident rate of
38.6 per 100,000 and prevalence of 6 per 1000 for ASD (Jensen et al., 2014; Newschaffer et
al., 2007); and incidence rate of 9.9 per 100,000 and prevalence of 1 per 1000 for ADHD
(Holden et al., 2013)). The low incidence of behavioural disorders in the general population
warrants careful consideration in light of the consequences associated with untreated
maternal depression and the risks this pathology poses for the health and wellbeing of the
mother and child. Ultimately, this is clearly an area that requires further research with an
emphasis on discerning the effects of maternal SSRI treatment from maternal
psychopathology on the neurodevelopment and risk for associated disorders in offspring.
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3.1 The behavioural and biological effects of maternal SSRI treatment on exposed
offspring: Evidence from animal studies
Given the inherent difficulties in assessing the effects of developmental SSRI exposure in
humans, researchers have turned to animal models to gain a deeper understanding of the
effects of maternal SSRI treatment on exposed offspring. To begin translation of the findings
from animal models to the clinic, emphasis needs to be placed on the timeline of SSRIexposure, and the equivalent neurodevelopmental milestones reached compared to
humans. In humans, the blood brain barrier is established at 23-32 weeks gestation, whilst
gliogenesis, synaptogenesis and myelination contribute to the peak brain growth occurring
at 36-40 weeks gestation (reviewed in Semple et al., (2013)). In rodents, these same
milestones are reached at PN1 – 3 and PN7 – 10, respectively (Semple et al., 2013). Indeed,
it has been estimated based on neurodevelopmental comparisons that rodent PN7 is
equivalent to birth in humans (Clancy et al., 2007). Typically, rodent studies are divided into
those that deliver SSRIs to dams during gestation (+/- lactation) and others that deliver SSRIs
directly to pups in the early postnatal period. Despite wide variance in other methodological
considerations, including drug dosage, administration method and treatment duration, it is
clear that SSRI exposure in rodent models can alter neurodevelopment in ways that impact
behavioural characteristics of offspring, including increases in anxiety- and depressive-like
behaviours, as well as abnormalities in social interaction and exploratory behaviours (Table
3). With the exception of a few studies (Boulle et al., 2016a, 2016b; Glover et al., 2015;
Kiryanova et al., 2016; Rayen et al., 2011), the current body of animal literature, does not
assess the effects of SSRIs in a depression or anxiety model, overshadowing the clinical
relevance of results. Considering depression and anxiety are associated with altered
serotonergic development in their own right (Nulman et al., 2012), modelling SSRI exposure
in a model of depression or anxiety that mimics the underlying serotonergic pathology may
influence the effects of SSRIs on the serotonergic system.
Of the 13 studies assessing maternally administered SSRIs, 12 report significant increases in
anxiety- or depressive-like behaviour and/or deficits in cognition in offspring ranging in age
from PN8 to PN140 (Table 3). Specifically, seven of these studies demonstrated an increase
in anxiety-like behaviours following doses ranging from 0.3 – 25mg/kg Fluoxetine (Bairy et
al., 2006; Boulle et al., 2016b; Lisboa et al., 2007; Noorlander et al., 2008; Olivier et al.,
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2011; Smit-Rigter et al., 2012) and 10mg/kg citalopram (Sprowles et al., 2016), with
exposure durations from GD0 to PN21. Six studies reported increases in depressive-like
behaviour measured by the forced swim test, shock escape test and novelty-supressed
feeding test (Boulle et al., 2016a; Glover et al., 2015; Lisboa et al., 2007; Noorlander et al.,
2008; Rayen et al., 2011; Sprowles et al., 2016). Conversely, six studies found either no
differences (Glover et al., 2015; Rayen et al., 2011), or decreases in anxiety-like behaviour
(Francis-Oliveira et al., 2013; Kiryanova et al., 2016; McAllister et al., 2012), and no changes
(Francis-Oliveira et al., 2013; Olivier et al., 2011) or decreases in depressive-like behaviour
(Francis-Oliveira et al., 2013; McAllister et al., 2012). In addition, five studies assessed
cognition, with one noting significant deficits in the passive avoidance test (Bairy et al.,
2006), and another reporting reduced performance in the Morris water maze in SSRIexposed offspring; the latter study also reported increased prepulse inhibition (Sprowles et
al., 2016). On the contrary, other studies reported no changes (Kiryanova et al., 2016;
McAllister et al., 2012; Olivier et al., 2011), or increases in cognition (spatial memory) in the
Morris water maze (Bairy et al., 2006). The differences in findings may be attributable to
differences in drug dosages, subject sex and behavioural test protocols (Table 3). For
example, one study reported a decrease in ambulation during the OFT in males only, but not
females, and an increase in immobility time in the forced swim test specifically in females,
following maternal fluoxetine exposure (Lisboa et al., 2007). Another study reported
negligible alterations in the behaviour of female rodents exposed to a high dose of
fluoxetine (McAllister et al., 2012), excluding males from the study. Further studies are
required to assess the dose effects of SSRI exposure on offspring behaviour of both sexes.
Studies examining the effects of postnatal SSRI exposure (ranging from PN0 – PN21) on
offspring behaviour provided the greatest consistency in findings (Table 3). All studies
reported significant increases in anxiety-like behaviour evident through decreases in
exploration and/or increases in anxiogenic parameters in the open field test, elevated plus
maze, light-dark test, novelty-induced hypophagia and novelty-suppressed feeding tests
(Ansorge et al., 2008, 2004; Karpova et al., 2009; Lee, 2009; Lee and Lee, 2012; RodriguezPorcel et al., 2011; Zheng et al., 2011). Three studies assessed the effects of postnatal
exposure on offspring depressive-like behaviour. Of those, two reported increases in
learned helplessness in the shock escape test (Ansorge et al., 2008, 2004) and one reported
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decreased immobility time in the forced swim test (Karpova et al., 2009). The conflicting
findings of the three latter studies are likely to be attributable to the different behavioural
tests used to measure depressive-like behaviour, given that the drug dose and
administration methods were similar. Indeed, although the forced swim test has been
validated as an effective measure of antidepressant efficacy and depressive-like behaviour
in rodents (Slattery and Cryan, 2012), others have suggested that in some cases immobility
behaviour may resemble a survival mechanism rather than behavioural despair (Nishimura
et al., 1988). Despite the relative consistency in findings of these studies exposing offspring
to SSRIs postnatally, translation of the results must be taken with caution. In the clinical
scenario, SSRIs are transferred via the mother in utero or through breast milk, which has
been shown to influence the pharmacokinetics of SSRIs (Heikkinen et al., 2002; Velasquez
and Bonnin, 2016). Therefore, directly exposing offspring to SSRIs postnatally could have an
exaggerated influence on their behaviour and neurobiology. Nonetheless, these consistent
findings suggest that the first 14 days of postnatal development in rodents, (third trimester
in humans (Clancy et al., 2007)), a period marked by peak brain growth (Semple et al.,
2013), represents a time period perhaps more vulnerable to the effects of developmental
SSRI exposure.
As previously mentioned, the majority of animal studies assess the effects of developmental
SSRI exposure in naïve rodents. A limited number assess the effects in models of maternal
depression (Boulle et al., 2016a, 2016b; Glover et al., 2015; Kiryanova et al., 2016; Rayen et
al., 2011), which arguably represents the clinical scenario more closely. Several studies have
modelled SSRI exposure in dams exposed to environmental stress (as a model of maternal
depression) through restraint, intense light exposure, confinement or other stressors (Table
3) (Boulle et al., 2016b, 2016a; Kiryanova et al., 2016; Rayen et al., 2011). Of those studies,
two reported increased depressive-like behaviour in the forced swim test in SSRI-exposed
offspring of maternally stressed dams (Boulle et al., 2016a; Rayen et al., 2011). Boulle et al.,
(2016a) reported an increase in immobility in the forced swim test in fluoxetine exposed
female (but not male) Boulle et al., (2016b)) offspring regardless of maternal stress, whilst
Rayen et al., (2011) reported increased immobility time in fluoxetine-exposed offspring of
maternally stressed dams only. Another reported that SSRI-exposed offspring born of dams
subjected to stress have decreased anxiety-like behaviour compared to SSRI-exposed
31

offspring born of dams naïve to stress (Boulle et al., 2016b). Similarly, Kiryanova et al.,
(2016) reported a reduction in anxiety-like behaviour in male offspring of maternally
stressed dams exposed to fluoxetine, suggesting that exposure could be beneficial in
ameliorating the effects of maternal mood on offspring, at least in relation to anxietyrelated behaviour. In comparison to these studies, another study investigated the effects of
maternal SSRI exposure in selectively bred rats to determine whether innate disturbances in
emotional behaviour altered susceptibility (or resistance) to the effects of paroxetine
treatment in offspring (Glover et al., 2015). Using selectively bred Sprague-Dawley rats that
exhibited decreased anxiety-like behaviour (high responders) or increased anxiety-like
behaviour (low responders), Glover et al., (2015) showed significantly greater immobility
times (depressive-like behaviour) in the forced swim test in offspring of paroxetine-treated
low responder dams, but no other differences in any parameters of the open field test,
forced swim test and elevated plus maze (Glover et al., 2015). Taken together these findings
suggest that the effects of developmental SSRI exposure can differ substantially in models of
maternal adversity and depression (which appears to reflect the findings observed in the
clinic). Furthermore, animal studies have highlighted an influence of sex on the effects of
SSRI exposure in offspring that warrants further investigation.
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Table 3: Effects of maternal antidepressant administration on biological measures in exposed offspring: evidence from animal studies.
Study
(Shaded studies
indicates those
implementing
models of maternal
depression/adversit
y).

Species, Strain, Drug Dose, Route and
Duration

Test and age performed

Main Findings:
(SSRI-exposed offspring compared to control unless
otherwise stated. Percentages given are approximations)

Species/Strain
Wistar Rats (n= 16 offspring/group)

PN8-49 (pre-adolescence
to adolescence)

Dose
Fluoxetine 8 and 12mg/kg

Negative Geotaxis (NG)
Open Field Test (OFT)
Rotarod Test (RT)
Morris Water Maze
(MWM)
Elevated Plus Maze (EPM)
Passive Avoidance (PA)

NG – Flx 8mg/kg increased time to turn 180o at PN10
(+20%) and PN12 (+53%).
Flx 12mg/kg decreased time to turn 180o at PN10 (-6%) an
increased time at PN12 (+44%)

Prenatal/maternal exposure
Bairy et al., (2006)

Route and Duration
GD6 – GD20 Oral (dissolved in water)

OFT – Increased central, peripheral and total crossings at
PN18 (Flx 8mg/kg: +320%, +127% and +133%. Flx
12mg/kg: +136%, +110% and +110%). Decreased central,
peripheral and total crossings at PN35 (Flx 8mg/kg: -52%, 15% and -20%. Flx 12mg/kg: -38%, -23% and -25%). No
differences on PN56.
RT – Increased retention time at PN22 (Flx 12mg/kg:
+350%) and PN49 (Flx 8 and 12mg/kg: +70%)
MWM – Flx 8mg/kg: Decrease in time to escape at PN24 (29%). Flx 12mg/kg decrease time to escape at PN24 and
PN29 (-32% and -50%).
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PA – Flx 12mg/kg: increase in latency to enter dark
compartment (+96%)
EPM – No significant differences
Summary – SSRI exposure caused a transient delay in
motor development, favourable effect on cognition and
learning at higher doses and decreased exploratory
behaviour at adolescence.
Glover et al., (2015)

Species/Strain
Sprague-Dawley Rats (high responders
and low responders, n= 24
offspring/group)
Dose
Paroxetine 10mg/kg

PN75 (Adult)
Locomotor response to
novelty (LRN)
EPM
Forced Swim Test (FST)

FST – exposed low-responders had increased immobility
compare to vehicle low-responders (+50%).
LRN and EPM – no differences
Summary – SSRI exposure exacerbated low-responder’s
depressive-like behaviour but had no effect on high
responders.

Route and Duration
7 days prior to mating – PN21 Oral
(dissolved in water)
Lisboa et al., (2007)

Species/Strain
Swiss Mice (n= 9-17 offspring/group)

PN30-40 (Adolescence)
and PN70 (Adult)

Dose
Fluoxetine 7.5mg/kg

OFT
EPM
FST
Intruder-resistant test (IRT)
Hot plate test (HPT)

Route and Duration
GD0 – PN21 Gavage

Male:
OFT – Decreased ambulation at PN40 (-16%)
IRT – Increased latency to first attack (+65%)
EPM, FST and HPT – no differences
Summary – Males: SSRI exposure induced decreased
exploratory behaviour at adolescence and decreased
reactivity/impulsivity in adults.
Female:
FST – Increased immobility both PN30 (+41%) and PN70
(+22%)
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OFT, EPM and HPT – no differences
Summary - Females: SSRI exposure increased depressivelike behaviour at both adolescence and adulthood.

Kiryanova et al.,
(2016)

Species/Strain
C57BL/6 Mice (n= 16-17
offspring/group)
Dose
Fluoxetine 25mg/kg
Route and Duration
GD15 to PN12 Oral (dissolved in
drinking water)

PN56 (Adult)
OFT
EPM
Passive Avoidance Test
(PAT)
MWM
Prepulse Inhibition (PPI)
IRT
Social Behaviour (SB)

EPM – Increase time in open arms in both stressed and
non-stressed offspring (+96%).
IRT – Increase in time spent (+223%) engaged in
aggressive behaviour.
OFT, PAT, MWM and PPI – no difference
Summary – SSRI exposure caused decreases in anxiety and
increases in aggression in adulthood, largely independent
of maternal stress.

Stress (maternal depression model)
Combination of restricted access to
food, continuous lighting, cage tilt,
foreign object in cage, paired housing
of dams, soiled cage, irregular tones,
restraint and white noise from GD4 –
GD18.
Olivier et al., (2011)

Species/Strain
Wistar Rats (n= 7-16 offspring/group)

PN28-35 (Adolescence)
and PN65 (Adult)

Dose
Fluoxetine 12mg/kg

Novelty Suppressed
Feeding (NSF)
OFT
EPM
Conditioned Place Aversion
(CPA)

Route and Duration
GD11 – PN1 Gavage

NSF – increased latency to start eating (+110%)
CPA – increased freezing time in the shock compartment
(+5%)
EPMS – decreased time spent in open arms (-45%)
AdSP – decreased amount of pinning behaviour (-46%)
OFT, EPM, FST, SPT, ASP and SeB – no difference
Summary – SSRI exposure caused increases in anxiety-like
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Noorlander et al.,
(2008)

Species/Strain
C57BL/6 Mice (n= 5-13
offspring/group)
Dose
Fluoxetine 0.3, 0.6 or 0.8mg/kg
Fluvoxamine 4.2mg/kg

EPM – After Stress (EPMS)
FST
Sucrose Preference Test
(SPT)
Adolescent Social Play
(ASP)
Adult Social Play (AdSP)

behaviour. No effect on depressive-like behaviour was
observed.

P20 (pre-adolescence) and
PN90 (adult)

EPM – increased duration in closed arms at both PN20
(Flx: +23%, Flv: 14%)
OFT – decreased distance travelled in the centre arena at
adulthood (Flx: -56%)
NSF – increased latency to feed at adulthood (Flx: +240%)

EPM
OFT
NSF

Summary – SSRI exposure caused increases in anxiety-like
and depressive-like behaviour

Route and Duration
GD8 – 18 Intraperitoneal (IP)
McAllister et al.,
(2012)

Species/Strain
C57BL/6 Mice (n= 16-17
offspring/group)
Dose
Fluoxetine 25mg/kg
Route and Duration
GD15 – PN12 Oral (dissolved in
drinking water)

PN73 – 83 (adult)
EPM
OFT
Horizontal Ladder (HL)
FST
MWM
PPI
Fear Conditioning (FC)

EPM – reduced time spent in closed arms (-21%)
FST – longer latency to first bout of immobility (+25%)
OFT, HL, MWM, PPI and FC – no difference
Summary – SSRI exposure caused decreases in anxietyand depressive-like behaviours.
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Boulle et al., (2016a)

Boulle et al., (2016b)

Species/Strain
Sprague-Dawley Rats (n= 13-16
offspring/group)
Dose
Fluoxetine 5mg/kg

PN140 (adult)
OFT
Elevated Zero Maze (EZM)
FST

Route and Duration
PN1 – PN21 Osmotic Minipumps

Male:
OFT – Fluoxetine exposure decreased centre crossing in
naïve offspring compared to maternally stressed offspring
(-50%).
FST – decreased escape driven behaviour in maternally
stressed offspring regardless of treatment (-12%).
EZM – no differences
Summary – In male offspring SSRI exposure in
combination with maternal stress decreased anxiety-like
behaviour.

Stress (maternal depression model)
Restraint 3x daily under bright light for
45 minutes from GD15 – GD21.

Female:
FST – increased immobility (+100%)
OFT and EZM – no differences
Summary - In females, SSRI exposure increased
depressive-like behaviour regardless of maternal stress.

Rayen et al., (2011)

Species/Strain
Sprague-Dawley Rats (n= 9-11
offspring/group)
Dose
Fluoxetine 5mg/kg
Route and Duration
PN1 – PN21 Osmotic Minipumps

PN32 (adolescence)
OFT
FST

FST – Increased immobility in offspring born of maternally
stressed dams (+150%).
OFT – no difference
Summary – SSRI exposure reversed the decrease in
depressive-like behaviour observed in unexposed
maternally stressed offspring.

Stress (maternal depression model)
Restraint 3x daily under bright light for
45 minutes from GD15 – GD20.
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Francis-Olivier et al.,
(2013)

Species/Strain
Wistar Rat

PN35 (adolescence) and
PN75 (adult)

Dose
Fluoxetine 5mg/kg

SPT
NSF

NSF – decreased latency to feed at adolescence (-30%)
SPT – no difference
Summary – SSRI exposure caused decreases in anxiety-like
and depressive like-behaviour in offspring at adolescence.

Route and Duration
GD0 – PN21 Gavage

Smit-Rigter et al.,
(2012)

Species/Strain
C57BL/6 Mice (n/group not specified)

Unknown age of testing

NSF – Increased latency to feed (+66%)

NSF

Summary – SSRI exposure caused increases in anxiety-like
and depressive like-behaviour in offspring.

PN60 (adult)

MWM – Increased latency to reach platform (+40)
OFT –decreased centre crossing (-66%, females only)
MB – increased burying of marbles (+140%)
PPI – increased response amplitudes (day 1, +280%; day 2,
+110%)
FST – decreased latency to first bout of immobility (-100%)

Dose
Fluoxetine 0.6mg/kg
Route and Duration
GD8 – GD18 IP

Prenatal/maternal exposure and postnatal/pup exposure
Sprowles et al.,
(2016b)

Species/Strain
Sprague-Dawley Rats (n= 9-23
offspring/group)
Dose
Citalopram 10mg/kg
Route and Duration (Dams)

Straight Channel Swimming
(SCS)
Cincinnati Water Maze
(CWM)
MWM
OFT
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GD6 – GD21 2x daily Subcutaneous
Injection (SC)
Route and Duration (Offspring)
PN1 – PN20 2x daily SC

EZM
Marble Burying (MB)
PPI
SB
FST

SCS, CWM, EZM and SB – no difference

PN30 (adolescence)

OFT – decreased locomotor activity (-23%)
RT – decreased latency to fall (-44%)

Summary – SSRI exposed offspring had alterations in
cognition and increased anxiety- and depressive-like
behaviour.

Postnatal/pup exposure
Lee and Lee (2012)

Species/Strain
Wistar Rats (n= 14-15/group)
Dose
Fluoxetine 20mg/kg

OFT
EPM
RT

Route and Duration
PN0 – PN4 SC

Ansorge et al.,
(2004)

Species/Strain
SERT Knockout Mice (+/+)( +/-)(-/-)
(n= 13-27/group)
Dose
Fluoxetine 10mg/kg
Route and Duration
PN4 – PN21 IP

PN84 (adult)
OFT
EPM

EPM – no difference
Summary – SSRI exposed offspring had increased anxietylike behaviour, evident through decreased exploratory
behaviour and impaired motor function.

OFT – decreased distance travelled (-40%), reduced total
ambulatory time (-38%) and vertical activity (-75%)
EPM – decreased entries into both arms (-30%)
NSF – increased latency to feed in (+/-) mice only (+130%)
SE – Increased latency to escape (+150%)
Summary – SSRI exposure increased anxiety- and
depressive-like behaviour evident through reduced
exploratory behaviours, increased latency to feed, and
increased latency to escape in SERT (+/+) and (+/-)
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offspring. Had no effect on SERT (-/-) offspring.

Ansorge et al.,
(2008)

Species/Strain
SERT Knockout Mice (+/+)( +/-)
(n= 32-65/group)
Dose
Fluoxetine 10mg/kg
Desipramine 10mg/kg
Citalopram 10mg/kg
Clomipramine 20mg/kg

PN84 (adult)
OFT
EPM
NSF
Novelty Induced
Hypophagia (NIH)
Shock Escape (SE)

OFT – reduced ambulatory time (-18 to -30%)
EPM – reduced entries into either arms (-10 to -22%)
NSF – increased latency to feed (+60 to +45%)
NIH – increased latency to drink (+83 to +100%)
SE – increased latency to escape (+25 to +38%)
Summary – SSRI exposed had increased anxiety- and
depressive-like behaviour and reduced exploratory
behaviour.

Route and Duration
PN4 – PN21 IP

Zheng et al., (2011)

Species/Strain
GFP-transgenic mice and wild-type
C57 mice. (n/group not specified)

PN91 (adult)

OFT – decreased distance travelled (-37%)

OFT

Summary – SSRI exposure increased anxiety-like
behaviour evident through decreased exploratory
behaviour.

PN110 (adult)

LDT – reduction in rearing (-42%) and increased immobility
(+11%)
OFT – reduced rearing (-30%) increased immobility in
central arena (+42%)

Dose
Fluoxetine (10mg/kg)
Fluvoxamine (10mg/kg)
Route and Duration
PN4 – PN21 IP

Karpova et al.,
(2009)

Species/Strain
C57BL/6 Mice (n= 9-12/group)
Dose
Fluoxetine (10mg/kg)

Light-Dark Test (LDT)
OFT
FST
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FST – decreased immobility time (-38%)

Route and Duration
PN4 – PN21 IP

Lee, (2009)

Species/Strain
Wistar Rats (n = 12 – 15/group)
Dose
Fluoxetine (10mg/kg)

Summary – SSRI-exposed offspring had increased anxietylike behaviour but reduced depressive-like behaviour.
PN30 – 35 (adolescence)
HPT
Gap-Crossing Test (GCT)
OFT

Summary – SSRI-exposed offspring exhibited greater pain
thresholds. Impaired environmental perception (gapcrossing test) and increased anxiety-like behaviour.

Route and Duration
PN0 – PN6 SC
Rodriguez-Porcel et
al., (2011)

Species/Strain
Long Evans Rats (n = 12 – 22/group)
Dose
Fluoxetine (5mg/kg)
Citalopram (10mg/kg)
Bupropion (15mg/kg)
Route and Duration
PN8 – PN21 2x daily SC

HPT – increased latency to first licking (+110%)
GCT – decreased crossable gap distance (-36%)
OFT – decreased total (-20%) and central (-37%)
ambulation and decreased rearing (-19%)

PN25 – 39 (adolescence)
Locomotor Tone (LT)
Novel Object Approach
(NOA)
Juvenile Play (JP)
PN89 – 184 (adult)
Object-Conspecific
Preference (OCP)
SB

Adolescence (PN25-39)
LT – increased immobility in response to tone (+180%)
NOA – reduced time spent investigating the novel object (33%) in males
JP – reduced pinning (-82 to -98%) in males and boxing in
both male (-71 to -80%) and females (-71%).
Adult (PN89-184)
OCP – reduced time spent investigating conspecific subject
(-58%)
SB – disrupted mounting behaviour
Summary – SSRI-exposure increased anxiety-like
behaviour and impaired social and sexual behaviour in
offspring.

Abbreviations: Flx = Fluoxetine; Flv = Fluvoxamine; GD = Gestational Day; PN = Postnatal Day; NG = Negative Geotaxis; OFT = Open Field Test; RT =
Rotarod Test; MWM = Morris Water Maze; EPM = Elevated Plus Maze; PA = Passive Avoidance Test; LRN = Locomotor Response to Novelty; FST = Forced
Swim Test; IRT = Intruder Resistant Test; HPT = Hot Plate Test; PAT = Passive Avoidance Test; PPI = Prepulse Inhibition Test; SB = Social Behaviour; NSF =
Novelty-Suppressed Feeding; CPA = Conditioned Place Aversion; EPMS = Elevated Plus Maze after Stress; SPT = Sucrose Preference Test; ASP = Adolescent
Social Play; AdSP = Adult Social Play; SeB = Sexual Behaivour; IP = Intraperitoneal; SC = Subcutaneous; HL = Horizontal Ladder; FC = Fear Conditioning; EZM
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= Elevated Zero Maze; CWM = Cincinnati Water Maze; MB = Marble Burying Test; SCS = Straight Channel Swimming; NIH = Novelty Induced Hypophagia;
SE = Shock Escape Test; LDT = Light-Dark Test; GCT = Gap-Crossing Test; LT = Locomotor Tone; NOA = Novel Object Approach; JP = Juvenile Play; OCP =
Object Conspecific Recognition
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There is mounting evidence from human and animal studies to suggest neurobehavioural
alterations in offspring exposed to SSRIs (Tables 1 and 3). Understanding the biological
foundations of such exposure might help elucidate causative mechanisms underlying
behavioural alterations and increased risk profiles, and assists in the development of
appropriate preventative strategies.
As SSRIs bind to and inhibit SERT, resulting in increased synaptic levels of serotonin, it is
reasonable to hypothesise that SSRI exposure could lead to altered development of aspects
of the serotonin system. Several studies have focused on the effect of developmental SSRI
exposure on the developmental expression of SERT. Specifically, it was reported that SERT
densities at adolescence (PN28) were significantly increased in the hippocampus, amygdala
and lateral hypothalamus, decreased in the dorsomedial hypothalamus and substantia
nigra, and unchanged in the raphe nuclei, of fluoxetine-exposed rodent offspring (CabreraVera and Battaglia, 1998). The findings indicated brain region specific changes and a
particular vulnerability of the limbic system (Cabrera-Vera and Battaglia, 1998).
Interestingly, the same study noted no significant differences in SERT densities between
exposed and control groups at adulthood (PN70), suggesting that the effects of
developmental SSRI exposure on SERT are transient in nature and become negligible in later
life (Cabrera-Vera and Battaglia, 1998). On the contrary another study reported reductions
in SERT expression in the raphe nucleus that persisted during adolescence (PN20) and
adulthood (PN90) following exposure to fluoxetine (Noorlander et al., 2008). The same
study also reported increases in anxiety- and depressive-like behaviour at both PN20 and
PN90 in offspring exposed to SSRIs in-utero, providing a potential behavioural translation to
the alterations in SERT expression (Noorlander et al., 2008). Another study assessing
serotonergic neurons in the raphe nucleus of offspring at PN56 reported marked reductions
in neuronal number and axonal terminals as a result of SSRI exposure (Silva et al., 2010). The
contrast in findings in the raphe nucleus between these studies (Cabrera-Vera and Battaglia,
1998 and Noorlander et al., 2008) may be attributed to the use of different species (rat vs.
mouse) as well as different drug doses and administration methods (10mg/kg s.c. vs.
0.8mg/kg i.p. fluoxetine). Interestingly, a high maternal fluoxetine dosage did not produce
longer lasting changes in SERT expression in the brain of offspring (Cabrera-Vera and
Battaglia, 1998), which seems paradoxical but may allude to a greater influence of the drug
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administration method used in these studies. Accordingly, unlike subcutaneous, the
pharmacokinetics of intraperitoneal injections parallels those administered orally given that
they are absorbed through the mesenteric vessels and undergo first pass metabolism by the
liver (Turner et al., 2011), and could result in a greater ratio of active metabolite to parent
drug.
Taken together, it may be suggested that SERT expression is altered through a) decreased
serotoninergic neurons at their origin (raphe nucleus) and hence decreased SERT
expression, and/or b) alterations in serotonergic afferents to areas including the
hippocampus and the subsequent altered expression of SERT, or c) the down/up-regulation
of SERT in response to increased extracellular serotonin. Surprisingly, given the effect of
SSRIs on the serotonergic system, there have been no studies to-date that have assessed
the potential alterations to serotonergic receptors or associated signalling. Considering that
SERT knock-out (KO) rodents have shown reduced 5HT1A receptor binding in the raphe,
hypothalamus, amygdala and septum (Li et al., 2000), and increased 5HT2A/2C receptor
binding in the hypothalamus and amygdala (Li et al., 2003), this is clearly an area that
warrants further investigation.
Given the neurotrophic role of serotonin during neurodevelopment (Gaspar et al., 2003),
animal studies have also focused on the effects of developmental SSRI exposure on
dendritic and neuronal mapping, and markers of neurogenesis, growth and development in
offspring (Table 4). All studies report significant cellular alterations to some extent with
varying SSRI exposure duration, dosage and exposure time points (Lee, 2009; Lee and Lee,
2012; Silva et al., 2010; Smit-Rigter et al., 2012; Swerts et al., 2010; Zheng et al., 2011).
Exposing embryos to SSRIs during gestation induced significant morphological alterations,
such as a decrease in neuronal number in the foetal frontal lobe at GD21 following 10mg/kg
fluoxetine treatment on GD9, 10 and 11 (Swerts et al., 2010). This study provides clear
evidence of neuronal alterations in exposed offspring; however, examination of any
potentially permanent alterations from birth to adulthood is required. Another study
assessed pyramidal neuronal complexity (quantified by measuring dendritic branching and
length) throughout adolescence to adulthood and reported a significant reduction in
complexity following administration of 0.6mg/kg/day fluoxetine to dams during GD8 – GD18
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(Smit-Rigter et al., 2012). The study provided evidence to suggest alterations caused by SSRI
exposure persist to adulthood.
As discussed previously, a limited number of animal studies assess the effects of
developmental SSRI exposure in clinically relevant models. Several recent studies have
assessed the effects of SSRI exposure on the neurobiology of offspring using a model of
maternal adversity by subjecting dams to stress (Boulle et al., 2016b, 2016a; Rayen et al.,
2011). Although varied in methodology, these studies collectively show significant influences
of SSRI exposure in animal models of stress (Table 4). One study reported a decrease in
hippocampal neurogenesis and proliferation, and increase in depressive-like behaviour in
adolescent offspring exposed to maternal stress (Rayen et al., 2011). The same study noted
that these findings were corrected when the offspring were also exposed to maternal SSRI
treatment (Rayen et al., 2011), suggesting that SSRI-exposure has the potential to reverse
the negative effects of maternal depression on offspring, at least in relation to hippocampal
neurogenesis. It has been widely suggested that the anti-depressive characteristics of SSRIs
occurs via downstream mechanisms by increasing BDNF expression and subsequent
neurogenesis (Martinowich and Lu, 2007). In contrast to this notion, one study assessing
SSRI-exposure during development showed reduced levels of hippocampal BDNF mRNA
expression in male and female offspring (Boulle et al., 2016a, 2016b). However, when
examined in a model of maternal adversity, it was shown that the SSRI exposure corrected
an observable increase in hippocampal BDNF induced by maternal stress in female offspring;
while in the males, exposure to maternal stress alone or in combination with fluoxetine
caused no effect (Boulle et al., 2016b). These sex-specific findings highlight the need for a
greater focus on assessing the influence of sex on SSRI exposure and outcomes of maternal
adversity.
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Table 4: Effects of maternal antidepressant administration on biological measures in exposed offspring: evidence from animal studies.
Study (Shaded studies Species, Strain, Drug Dose, Route and Duration
indicates those
implementing models
of maternal
depression/adversity).
Prenatal/maternal exposure
Fornaro et al., (2007)
Species/Strain
Sprague-Dawley rat dams. (n=9 to 11/group)
Dose
Fluoxetine (10mg/kg)

Analyses

Main Findings

Serotonin concentrations in
Placenta and foetal lungs

• Prenatal FLX exposure significantly reduced
(-38%) placental tissue serotonin content. Did
not alter lung serotonin content.

Rat foetuses were collected
via caesarean section on
GD21

Route and Duration
Oral gavage daily to dams from GD11 to GD21

Noorlander et al.,
(2008)

Species/Strain
Mice (C57BI/6-JIco) (n= 3-6/group)
Dose
Fluoxetine (0.3, 0.6 or 0.8mg/kg).

Dorsal raphe nucleus
examined via
autoradiography for SERT
binding (PN20 and PN90)

• Significant decreases at PN20 (-40%) and
PN90 (-53%) in SERT binding in the raphe
nucleus after prenatal exposure to FLX
compared to controls (dose-dependent
exposure).

Route and Duration
I.P. injection daily to dams from GD8 to GD18.
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Cabrera-Vera &
Battaglia (1998)

Species/Strain
Sprague-Dawley Dams
(n= 7/group)
Dose
Fluoxetine (10mg/kg)

PN28 and PN70
Cortex, hippocampus,
septum, amygdala, basal
ganglia and raphe nucleus –
autoradiography for SERT
binding.

Route and Duration
S.C. injection daily to dams from GD13 to GD20

PN28 Following prenatal FLX exposure
• Significant increases in SERT densities in the
CA2 and CA3 areas of the hippocampus (+47%
and +38% respectively).
• Significant increases in SERT densities in
basolateral (+32%) and medial (+44%)
amygdaloid nuclei and lateral hypothalamus
(+21%) of offspring compared to controls.
• Significant reductions in SERT densities in
dorsomedial hypothalamus (-21%) and
substantia nigra (-19%)
•Nil significant differences in SERT densities in
raphe nucleus
PN70 Following prenatal FLX exposure
• nil significant differences in SERT densities in
any examined brain regions compared to
control

Female offspring
study
Boulle et al., (2016a)

Male offspring study
Boulle et al., (2015b)

Species/Strain
Sprague-Dawley Dams
(n= 7/group)
Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX
Dose

Offspring (PN168)
Hippocampus
- Quantitative reverse
transcriptase PCR (qRT-PCR),
analyses of genes associated
with BDNF/TrKB signalling
pathway
- Chromatin
immunoprecipitation (ChIP),

Female
• Significant decreases in hippocampal BDNF
exon IV mRNA levels in FLX-exposed offspring
(-10% non-stressed group; -20% stressed
group)
• Significant negative correlation (r = -0.33, p
= 0.02) between hippocampal BDNF exon IV
mRNA levels and immobility in the forced
swim test.

47

Fluoxetine (5mg/kg)
Route and Duration
Osmotic minipumps from PN1 to PN21.

quantification of fragments
of promoter regions of
target genes in BDNF/TrKB
signalling pathway

Stress (exposure to confinement and bright
light for 45min) induced on GD14 to assigned
dams, occurring 3x daily until end of pregnancy.

Morrison et al., (2004) Species/Strain
Sheep ewe (n=7-8/group)
Dose
Fluoxetine (98.5µg/kg)

Rayen et al., (2011)

Route and Duration
Polyvinyl catheters to dam for 8 days,
commencement ranged from GD118 – 122 ±4-5
days.
Species/Strain
Sprague-Dawley (n=9-11/group)
Groups
Prenatal stress + VEH
Prenatal stress + FLX
Control + VEH
Control + FLX

Male
• Significant decreases in BDNF IV (-20%) and
TrKB (-40%) mRNA expression in the
hippocampus of FLX-exposed offspring.
• Significant decreases in hippocampal BDNF
mRNA (-20%) expression of prenatally
stressed subjects regardless of treatment.

Foetal blood (sampled daily
during infusion period, 8
days).
- ACTH
- Cortisol
- FLX

• Significant increase (+115%) in FLX exposed
foetal plasma cortisol concentrations on
infusion day(s) 6, 7 and 8.

Immunohistochemistry
(PN42)
- Hippocampus and dentate
gyrus number of
proliferating cells and
immature neurons.

• FLX exposure significantly reversed the
decrease in hippocampal cell proliferation
and hippocampal neurogenesis in prenatally
stressed offspring to levels comparable to
control.

• Significant increase (+102%) foetal plasma
ACTH concentrations on infusion day 7 in FLX
exposed

Dose
Fluoxetine (5mg/kg)
Route and Duration
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Osmotic minipumps to dams from PN1 to PN39.

Smit-Rigter et al.,
(2012)

Species/Strain
Mice (C57/BL6J)
Dose
Fluoxetine (0.6mg/kg)
Route and Duration
I.P. injections to dams from GD8 – GD18.

Swerts et al., (2010)

Species/Strain
Wistar Rats
Dose
Fluoxetine or Imipramine (10mg/kg)
Route and Duration
I.P. injections to dam on GD9, GD10 and GD11

Offspring brains collected to
determine complexity of
dendritic tree of layer 2/3
pyramidal neurons in the
somatosensory cortex at
three ages (PN6-9, PN60 and
PN>365).
Complexity of dendritic tree
was quantified using the
Dendritic Complexity Index
(DCI), which takes into
consideration dendritic
branching and dendritic
length.
Dams euthanized GD21, and
foetuses extracted.

• Significant reduction (~50%) in complexity
of 2/3 pyramidal neurons of fluoxetine
exposed animals. Reduction in complexity was
evident at all life stages (PN6-9, PN60,
PN>365)

• Significant decreases in the number of
frontal lobe neurons in FLX (-6%) and IMIP (23%) exposed offspring compared to control

Foetal brains collected and
analysed via optical
microscope for visual
quantification of frontal lobe
nerve cell bodies.
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Postnatal/pup exposure
Silva et al., (2010)
Species/Strain
Wistar Rat pups (n=5/group)
Dose
Fluoxetine (10mg/kg)
Route and Duration
S.C. injections daily to pups from PN1 to PN21

2 months of age (~PN56)
subject brains collected for
morphometric analysis of
5HT neurons in the dorsal
(DR) and median (MnR)
raphne nuclei, and
hippocampal dentate gyrus
(DG).
Morphometric parameters
of serotonergic neurons
- Perimeter (PER)
- Maximum, minimum and
median diameters (Dmax,
Dmin and Dmed).

Lee (2009)

Lee & Lee (2011)

Species/Strain
Wistar Rat Pups (n=36 to 42/group)

PN7 and PN35

Dose
Fluoxetine (10mg/kg)

Dil Labelling of
Thalamocortical Afferents
(somatosensory cortex)

Route and Duration
S.C. injections daily to pups from PN0 to PN6.

Golgi-Cox impregnation
(somatosensory cortex)

Species/Strain
Wistar Rat Pups (n=7 to 9/group)
Dose

PN35
Immunochemistry
- cerebellum (Purkinje cells)
Golgi-Cox Impregnation

• Significant reduction in neuron number of
the DR (-26%), and reduced 5HT terminals (63%) in the DG of FLX exposed compared to
vehicles.
• Significant reduction in all morphometric
parameters of serotonergic neurons.
DR
- Perikaryal area (-18%), Dmax (-9.6%), Dmin (17%), Perikaryal perimeter (-9.6%).
MnR
- Perikaryal area (-23%), Dmax (-13%), Dmin (10%), Dmed (-14%) Perikaryal perimeter (13.5%).
• Significant reduction (-51%) in number of
terminal tips of Thalamocortical afferent
arbors
• Significant reduction in dendritic field (27%), shorter dendritic length (-20%) and
fewer terminal endings (-20%) in FLX exposed
compared to vehicle.
• Significant reduction in dendritic spines of
the 2nd (-43%), 3rd (-42%) and 4th (-40%)
dendritic orders.
•Significant reduction in bifurcation nodes (25%), terminals (-25%) and dendritic length (38%) of medium spiny striatal neurons and
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Fluoxetine (20mg/kg)
Dose and Duration
S.C. injections daily to pups from PN0 to PN4

Zheng et al., (2011)

Species/Strain
Male GFP-Transgenic mice or wild-type C57
mice
Dose
Fluoxetine or Fluvoxamine (10mg/kg)
Route and Duration
I.P. injections daily to pups from PN4 to PN21

- Striatum (dendritic
structure)
- Layer 5 pyramidal neurons
of primary motor cortex

Layer 5 pyramidal M1 neurons.

Confocal imaging of
hippocampus neuronal
development – spinal
densities of CA1 neurons
were assessed at PN22
(adolescence) and PN90
(adult) stages.

• Significant reduction (-10%) in spine density
of basal dendrites at PN22 of SSRI exposed
groups

• No significant differences in Purkinje cell
density and soma size between treatment
groups

• Significant reduction (-16%) in spine density
of apical dendrites at PN22 of those exposed
to fluvoxamine
• Significant increase (+15%) in spine density
of basal dendrites at PN90 of SSRI exposed
groups

• Significant increase (+13%) in spine density
of apical dendrites at PN90 of those exposed
to fluoxetine.
Abbreviations: FLX = fluoxetine, DA = dopamine, NE = norephinephrine, 5-HT = 5-hydroxytryptamine receptors, DOPAC = 3,4-dihydroxyphenylacetic acid,
5-HIAA = 5-hydroxyindoleacetic acid, HVA = homovanillic acid, s.c. = subcutaneously, SERT = serotonin transporter, GD = gestational day, PCo2 = partial
pressure of carbon dioxide, PO2 = partial pressure of oxygen, ACTH = adrenocorticotropic hormone, i.p. = intraperitoneal, CBG = corticosteroid binding
capacity, GR = glucocorticoid receptor, GRIP1 = glucocorticoid receptor interacting protein, MR = mineralcorticoid, DCX = doublecortin, IMIP = imipramine.
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3.2 Considerations for Animal Studies
Animal studies, whilst being a step away from the clinic, have begun to address the question
of whether the reported adverse effects of maternal SSRI treatment on offspring are the
result of SSRI exposure or a response to innate maternal depression and/or adversity.
However, a number of limitations and challenges arise when translating preclinical findings
to the clinical scenario. Firstly, with the exception of studies that model maternal depression
using environmental stressors, most studies administer SSRIs to healthy dams, which does
not represent the clinical scenario. Indeed, the very presence of maternal depression, a
disorder characterized by an underlying serotonergic pathology, could influence the effects
of maternal SSRI exposure on offspring. One current animal model of depression, the
Wistar-Kyoto rat (WKY), exhibits serotonergic and behavioural abnormalities similar to
human depressive disorder (Arango et al., 2001; Lemos et al., 2011; Paré, 1994; Pare and
Tejani-Butt, 1996; Quan-Bui et al., 1984; Scholl et al., 2010; Sullivan et al., 2006; Zhang et al.,
2005) and could provide an invaluable tool for investigating the effects of SSRI exposure in a
more clinically relevant setting. For example, the WKY exhibits increased anxiety- and
depressive-like behaviour, decreased basal serotonin and 5HIAA concentrations, decreased
SERT density in hippocampal and cortical brain regions, decreased 5HT1a receptor density
and a reduction in the serotonin rate limiting enzyme, tryptophan hydroxylase; all of which
have been reported in clinical cases of MDD (Arango et al., 2001; Lemos et al., 2011; Paré,
1994; Pare and Tejani-Butt, 1996; Quan-Bui et al., 1984; Scholl et al., 2010; Sullivan et al.,
2006; Zhang et al., 2005). Acknowledging that MDD is not characterised by abnormalities in
the serotonergic system alone, these serotonergic alterations in both clinical cases of MDD
and the WKY rat could underpin significant differences in response to SSRI exposure
compared to the response observed in otherwise healthy subjects. Furthermore, the few
animal studies modelling maternal adversity have shown that maternal SSRI treatment
differentially affects offspring neurodevelopment and behaviour compared to subjects born
of dams absent of adversity (Boulle et al., 2016a, 2016b; Kiryanova et al., 2016; Rayen et al.,
2011). Overall, further research utilising appropriate models of depression or adversity are
required in order to determine the effects of maternal SSRI exposure on offspring in a
clinically relevant setting.
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The second limitation to consider when interpreting evidence from animal models is the
variation in SSRI dosages and treatment duration between studies. Fluoxetine, which
appears to be the SSRI of choice for animal studies, ranges in dosages from 0.3mg/kg to
25mg/kg in animal studies whilst in the clinic, daily fluoxetine doses of 20 – 80mg are
commonly prescribed (Beasley et al., 2000). Further investigation into the dose range that is
clinically relevant for rodent studies is required. The critical neurodevelopmental time
period which SSRI exposure confers the greatest changes are also unknown. As such,
variance in the timing and duration of SSRI exposure during and after gestation remains a
major difference in methods between rodent studies (Tables 3 and 4). As previously
discussed animal studies can be divided into those that administer SSRIs maternally, thereby
indirectly exposing offspring (similar to the clinical scenario), or those that directly
administer SSRIs to offspring in early life. Neurodevelopmental milestones occurring in
rodents between PN1 – PN10 are equivalent to those occurring during 23 – 40 weeks
gestation in humans (Semple et al., 2013). Thus, postnatal exposure in rodents represents
developmental exposure during the third trimester in humans only and should be
interpreted as such. It is still unclear from human studies whether there are periods either
during pregnancy or after that confer greater risks associated with SSRI exposure. Further
animal studies are required to examine the time-dependent effects of developmental SSRI
exposure on offspring.
Finally, animal studies have been useful in the assessment of the molecular effects of SSRI
exposure on offspring; however, they have largely focused on the serotonergic system and
neuronal topography, with evidence suggesting that SSRI exposure can produce alterations
to serotonergic (Raphe) neuronal number, SERT densities and neuronal/dendritic mapping
in offspring (see Table 4.). Further examination of other neurotransmitter systems
implicated in the neurobiology and pathology of various developmental neuropsychiatric
disorders is required. Human studies have suggested an increased risk of ADHD, ASD and
depression in SSRI-exposed offspring; disorders which are characterized by gross alterations
in glutamatergic, GABAergic and neurotrophic signalling (Brambilla et al., 2003; Castrén and
Rantamäki, 2010; Coghlan et al., 2012; Dölen et al., 2007; Duman et al., 2000; Dwivedi et al.,
2003; Hashemi et al., 2016; Hashimoto, 2010; Homberg et al., 2014; Kim et al., 1982; Knable
et al., 2004; Küçükibrahimoğlu et al., 2009; Lin and Sibille, 2013; Mitani et al., 2006;
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Sanacora et al., 2012). Indeed, the purported increased risk of inducing developmental
disorders associated with maternal SSRI exposure could be related to the perturbed
development of a range of systems, not only serotonin itself. Investigation of other
neurotransmitter and neurotrophic systems would provide valuable insight into broader
alterations caused by maternal SSRI exposure and form a basis for future studies.

4. Concluding Remarks
In conclusion, the current body of evidence suggests that maternal SSRI treatment may
cause

perturbations

to

the

neurobiology,

behaviour

and

ultimately

risk

for

neurodevelopmental disorders in exposed offspring. However, conflicting findings do persist
and the evidence summarised in the current review regarding the safety of SSRI use during
pregnancy or whilst breast feeding is far from conclusive. Evidence from human studies
suggest that SSRI exposure during neurodevelopment may be associated with an increased
risk for neurodevelopmental disorders, such as ADHD and ASD, and mood disorders
including depression; however, these studies are often confounded by the presence of the
underlying maternal psychopathology. Difficulties in quantifying or accounting for the
symptom severity of the maternal psychopathology are often inherent to clinical studies,
and since SSRI treatment could be phenotypically masking symptoms, the findings warrant
careful consideration. Furthermore, given that untreated maternal depression and adversity
themselves are associated with an increased risk for neurodevelopmental disorders;
maternal SSRI use could in fact be a marker of symptom severity of the underlying mood
disorder, which itself contributes to the reported risk. Contrary to this notion, preclinical
studies have reported alterations in behaviour and neurobiology in offspring as the result of
developmental SSRI-exposure in otherwise healthy animals, suggesting that SSRI exposure
can cause long lasting perturbations to neurodevelopment, irrespective of the innate
maternal mood disorder. Although valuable in assessing the effects of developmental SSRIexposure in isolation, these studies are limited by the fact that they use healthy or naïve
animals otherwise free of any underlying psychopathology. In the clinic, SSRI treatment and
an underlying mood disorder occur in combination and it may be that the underlying mood
disorder confers a degree of resistance (or exacerbation), or at least influences the effects of
SSRI-exposure on offspring. The pervading question that remains unanswered is: if SSRI use
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does increase the risk of neurodevelopmental disorders in offspring, which of the two
factors - the underlying maternal psychopathology or the SSRI treatment – has a greater
influence on this risk. Further research utilizing models of depression is required in order to
clarify the answer to this question in a manner that truly discerns the effects of SSRIexposure from the innate maternal mood disorder on offspring neurodevelopment and risk
for associated disorders. Considering the number of women prescribed ADDs during
pregnancy, further research into this area is warranted.
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